Evidence map›Paper›PMID 34474675›Full record

Observational studyBMC urology2021

The use of mono- and combination drug therapy in men and women with lower urinary tract symptoms (LUTS) in the UK: a retrospective observational study.

Mahmood Ali, Margarita Landeira, Patrick J O Covernton, Nurul Choudhury, Ashley Jaggi, Francis Fatoye, Rob van Maanen

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Mahmood Ali *Manchester Metropolitan University, Manchester, UK. mmd.ali01@gmail.com.
Margarita Landeira *Astellas Pharma Europe Ltd, Addlestone, UK.
Patrick J O CoverntonAstellas Pharma Europe Ltd, Addlestone, UK.
Nurul Choudhury *Astellas Pharma Europe Ltd, Addlestone, UK.
Ashley Jaggi *Manchester Metropolitan University, Manchester, UK.
Francis FatoyeManchester Metropolitan University, Manchester, UK.
Rob van Maanen *Astellas Global Development, Leiden, The Netherlands.
Astellas Pharma (United Kingdom) · GBManchester Metropolitan University · GBAstellas Pharma (Netherlands) · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCombination drug therapy for lower urinary tract symptoms (LUTS) is beneficial to selected patients and recommended by guidelines. Patterns of real-world LUTS drug use, especially combination drug therapy, have not been studied extensively. Moreover, further understanding of the recent landscape is required following the introduction of the beta-3-adrenoceptor agonist mirabegron in the UK in 2013 for overactive bladder (OAB). The objective was to describe mono- and combination drug therapy use for LUTS in patients in UK clinical practice.

methodsThis was a retrospective, descriptive, observational database study using UK Clinical Practice Research Datalink GOLD and linked databases. Men and women ≥ 18 years with a first prescription for any LUTS drug from 2014 to 2016 with ≥ 12 months continuous enrollment pre- and post-index date were included. Primary endpoints were mono- or combination drug therapy use for LUTS in male and female cohorts. Secondary endpoints were description of treatment prescribed, treatment persistence and patient demographics. Data were analyzed descriptively. Sub-cohorts were defined by drugs prescribed at index date.

results79,472 patients (61.3% male) were included, based on index treatments. Of all men, 82.5% received any benign prostatic obstruction (BPO) drug, 25.4% any OAB drug, and 7.9% any BPO drug plus any OAB drug. As either mono- or combination drug therapy, 77.1% received an alpha-blocker, 18.9% a 5-alpha reductase inhibitor, 23.9% an antimuscarinic agent, and 2.1% mirabegron. Of all women, 94.5% received any OAB drug, 6.0% duloxetine, and 0.5% any OAB drug plus duloxetine. As either mono- or combination drug therapy, 87.7% received an antimuscarinic, and 9.7% mirabegron. In men or women receiving OAB treatment, approximately 2.5% received combination drug therapy with an antimuscarinic agent and mirabegron. For OAB drug monotherapies, mirabegron had the highest persistence in both male and female cohorts.

conclusionsThis study provides a better understanding of the recent landscape of LUTS drug use in UK clinical practice. It highlights potential undertreatment of storage symptoms in men with LUTS and the low use of combination OAB treatments.

Indexed as

5-alpha Reductase InhibitorsAcetanilidesAdolescentAdrenergic alpha-AntagonistsAdrenergic beta-3 Receptor AgonistsAdultAgedAged, 80 and overDrug Therapy, CombinationFemaleHumansLower Urinary Tract SymptomsMaleMiddle AgedMuscarinic AntagonistsRetrospective Studies5-alpha Reductase InhibitorsAcetanilidesAdrenergic alpha-AntagonistsAdrenergic beta-3 Receptor AgonistsmirabegronMuscarinic AntagonistsThiazolesUrological AgentsBenign prostatic obstruction (BPO)Lower urinary tract symptoms (LUTS)Overactive bladder (OAB)PersistenceStress urinary incontinence (SUI)

Identifiers

PMID34474675
PMCPMC8414666
OpenAlexW3137039981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.